China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor

China's medical products administrator accepted CStone Pharmaceuticals' (HKG:2616) manufacturing localization application for its pralsetinib RET inhibitor, according to a Tuesday filing with the Hong

MT NewswiresApr 8 21:52 ET

CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%

To the annoyance of some shareholders, CStone Pharmaceuticals (HKG:2616) shares are down a considerable 34% in the last month, which continues a horrid run for the company. For any long-term shareh

Simply Wall StMar 15 18:08 ET

Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved

Cstone Pharmaceuticals (HKG:2616) said China's National Medical Products Administration (NMPA) approved a supplemental biologics license application (sBLA) for sugemalimab in combination with fluoropy

MT NewswiresMar 15 02:40 ET

CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

Yahoo FinanceMar 15 00:05 ET

Insider Purchases Worth CN¥6.54m See Losses As CStone Pharmaceuticals Market Value Drops To HK$1.4b

The recent price decline of 31% in CStone Pharmaceuticals' (HKG:2616) stock may have disappointed insiders who bought CN¥6.54m worth of shares at an average price of CN¥2.52 in the past 12 months. In

Simply Wall StMar 4 18:49 ET

CStone Pharmaceuticals Removed From Hong Kong Stock Connect; Shares Plunge 26%

CStone Pharmaceuticals (HKG:2616) has been removed from the Hong Kong Stock Connect effective March 4, a Monday filing said. The removal from the Stock Connect program comes after the company was deli

MT NewswiresMar 4 01:22 ET